[68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects

This study aimed to develop a ready-to-use kit for Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freez...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of nuclear medicine and molecular imaging
Main Authors Signore, Alberto, Galli, Filippo, Varani, Michela, Campagna, Giuseppe, Bentivoglio, Valeria, Accardo, Antonella, Morelli, Giancarlo, Lauri, Chiara
Format Journal Article
LanguageEnglish
Published Germany 01.07.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study aimed to develop a ready-to-use kit for Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freeze-dried at -80 °C and radiolabelled at room temperature. In vitro quality controls (iTLC, HPLC, SDS-PAGE, spectrometry and binding assays on activated T-lymphocytes) and in vivo biodistribution studies in BALB/c mice, were performed. The shelf life of the lyophilized kits was assessed up to 6 months of storage, by iTLC, HPLC and SDS-PAGE. First-in-human study was conducted in 5 volunteers by performing [ Ga]Ga-THP-desIL2 PET/CT acquisitions at several time-points, to assess biodistribution and dosimetry. Mass spectrometry showed that only one molecule of THP or NODAGA is bound to N-terminus of both IL2 proteins. The most efficient conjugation was observed for THP-desIL2. [ Ga]Ga-THP-desIL2 showed higher labelling yield (LY) (59.13 ± 2.58%), radiochemical purity (RCP) (97.91 ± 0.45%) and binding affinity to its receptor on activated T-cells (Kd = 0.584 nM/L) and a more favorable biodistribution in pre-clinical studies, with rapid kidney metabolism and lower liver uptake than [ Ga]Ga-NODAGA-desIL2 and [ Ga]Ga-THP-hrIL2. Lyophilized kit of THP-desIL2 remained stable at -80 °C up to 6 months maintaining high RCP and LY. Phase I study showed a rapid plasma clearance, renal metabolism, safety and favorable dosimetry. We developed an efficient lyophilized kit of THP-desIL2 for Ga-labelling at room temperature in GMP conditions, obtaining excellent in vitro and in vivo results. [ Ga]Ga-THP-desIL2 PET/CT studies in humans showed favorable dosimetry and safety, thus highlighting its potential for a wide range of clinical applications, particularly in immune-mediated diseases and cancer.
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-025-07430-9